資源描述：
《凌丹康復方配合DC-CIK治療白血病臨床研究》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、凌丹康復方配合DC-CIK治療白血病臨床研究劉清池吳維海李剛榮胡曉東馮新旺梁春耕武大勇李慧慧宋淑花馬傳寶李建英王榮孝張慧敏牛景月［摘要］目的觀察屮藥凌丹康復方配合樹突狀細胞聯(lián)合細胞因子誘導的殺傷細胞(DC-CIK)治療口血病的臨床效果和安全性。方法病例選擇血液學緩解但未達到分子生物學緩解的白血病患者或殘留白血病檢測陽性患者，其屮急性白血病19例，慢性粒細胞白血病1例。用血細胞分離機采集患者的外周血單個核細胞，分別培養(yǎng)DC和CTK,然后再混合培養(yǎng)獲得DC-CTKo將DC-CIK經(jīng)靜脈回輸給患者，每15~20天回輸一次，共輸注
2、4?6次。同時服用扶正祛邪中藥凌丹康復方。觀察治療效果與安全性。結(jié)果凌丹康復方配合DGCIK治療20例緩解期白血病患者,達分子生物學緩解，標志基因轉(zhuǎn)陰4例，其中1例為AML1/ET0,1例CBF/MYH11,1例IgH基因重排，1例bcr/abl；微小殘留白血病轉(zhuǎn)為陰性者3例。治療后3年CR為75%沖位CR期25月(10?37月)。DC-CIK輸注后除5例出現(xiàn)一過性發(fā)熱，畏寒，無其它嚴重副作用。結(jié)論中藥凌丹康復方配合DC?CIK細胞治療血液學緩解后口血病，具有明顯清除微小殘留白血病細胞的作用，是血液學緩解后白血病患者合適的
3、選擇，靜脈輸注安全，冇較好的臨床應用前景?！娟P(guān)鍵詞】口血病，免疫治療，樹突狀細胞，殺傷細胞/細胞因子誘導，中藥ClinicalstudyofChineseherbs-lingdankangfufangandDC-CIK(dendriticcellsandcytokine-inducedkiller)combinedtreatmentforleukemiaLIUQing-chi,WUWei~hai,LIGang~rongfHUXiao-dong,FENGXin~wangfLIANGChun-gengWUDa-yong,LIH
4、ui~hui,SONGShu~hua,MAChuan~bao,LIJian-ying,WANGRong-xiao,ZHANGNIUJing-yue1,DepartmentofHematology,Ping'anHospital,2,MolecularBiologyLaboratoryofPing'anHospital,Shijiazhuang050021,ChinaAbstract:Objective:ToevaluatetheeffectivenessandsafetyofChineseherbs-lingdankang
5、fufangandDC?CIK(dendriticcellsandcytokine-inducedkiller)combinedtreatmentofleukemiapatientSeMethods:Selected20patientsachievedhematologicalcompleteremission(HCR)butnotachievedmolecularbiologicalremission(MBR)orminimalresidualLeukemia(MRL)positive.Among20patients19
6、caseswithacuteleukemiaandonecaseswithchronicmyelocyticleukemia..UsedCOBESeparatortoseparatetheperipheralbloodmonocyteofthepatientstoCultureDCandCIKrespective,andthenmixedtoCulture,andthemixedcultureswereintravenousinjectedtothepatientsself.Onceevery15?20daystointr
7、avenousinject,andthetotalwere4?6.AllpatientswereadministeredorallywithChineseherbs-lingdankangfufangeveryday.Toobservedtheeffectivenessandsafety.Results:In20patientsreceivedthetreatmentofChineseherbs-lingdankangfufangandDC-CIK,4caseachievedMBR,thatmarkedgenechange
8、negativeincluding2AML1/ETOJCBFB/MYHIland1bcr/abl,and3case(allwereacutenon-lymphocyticleukemia-M2)MRLchangenegative.The3years5CRprobabilityafterChinesehe
